T
Thomas Forst
Researcher at University of Mainz
Publications - 217
Citations - 6985
Thomas Forst is an academic researcher from University of Mainz. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 42, co-authored 205 publications receiving 6517 citations.
Papers
More filters
Journal ArticleDOI
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen Dungan,Santiago Tofe Povedano,Thomas Forst,José G. González,Charles Atisso,Whitney Sealls,Jessie L. Fahrbach +6 more
TL;DR: Once-weekly dulaglutide is non-inferior to once-daily liraglUTide for least-squares mean reduction in HbA1c, with a similar safety and tolerability profile.
Journal ArticleDOI
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control : Results from the pioneer study
Andreas Pfützner,Nikolaus Marx,Georg Lübben,Matthias R.W. Langenfeld,Daniel Walcher,Thomas Konrad,Thomas Forst +6 more
TL;DR: In this article, the anti-inflammatory and antiatherogenic effects of pioglitazone suggested by animal experiments are reproducible in man and independent from improvements in metabolic control.
Journal ArticleDOI
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1)
Matthew C. Riddle,Thomas Forst,Ronnie Aronson,Leobardo Sauque-Reyna,Elisabeth Souhami,Louise Silvestre,Lin Ping,Julio Rosenstock +7 more
TL;DR: In this paper, the efficacy and safety of lixisenatide in patients with HbA 1c still elevated after initiation of insulin glargine were examined in a double-blind, parallel-group trial.
Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
Matthew C. Riddle,Thomas Forst,Ronnie Aronson,Leobardo Sauque-Reyna,Elisabeth Souhami,Louise Silvestre,Lin Ping,Julio Rosenstock +7 more
TL;DR: Adding lixisenatide to insulin glargine improved overall and postprandial hyperglycemia and deserves consideration as an alternative to prandial insulin for patients not reaching HbA1c goals with recently initiated basal insulin.
Journal ArticleDOI
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
Andreas Pfützner,Thomas Forst +1 more
TL;DR: High-sensitivity CRP is recommended as a predictive laboratory marker for cardiovascular disease risk also in patients with diabetes mellitus and non-diabetes drugs that have been shown to reduce hsCRP concentrations include aspirin, statins, cyclooxygenase-2 inhibitors, and fibrates.